

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 May 2002 (23.05.2002)

PCT

(10) International Publication Number
WO 02/40034 A1

(51) International Patent Classification⁷: A61K 31/662, 31/355, 7/48, 7/02, 7/075, 7/16, C07F 9/141, A61P 17/16

(74) Agent: ALLENS ARTHUR ROBINSON PATENT & TRADE MARKS ATTORNEYS; 530 Collins Street, Melbourne, VIC 3000 (AU).

(21) International Application Number: PCT/AU01/01476

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:

14 November 2001 (14.11.2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:
60/247,997 14 November 2000 (14.11.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): TO-COVITE PTY LTD [AU/AU]; Level 2, 90 William Street, Melbourne, VIC 3000 (AU).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): WEST, Simon, Michael [AU/AU]; 3 Verdon Street, Williamstown, VIC 3016 (AU). VERDICCHIO, Robert, J. [US/US]; 8 Tania Court, Succasunna, NJ 07876 (US). KANNAR, David [AU/AU]; 182 Belgrave Hallam Road, Belgrave South, VIC 3150 (AU).

WO 02/40034 A1

(54) Title: COMPLEXES OF PHOSPHATE DERIVATIVES

(57) Abstract: There is provided a composition comprising the reaction product of: a) one or more phosphate derivatives of one more ore hydroxylated actives; and b) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.

Complexes of Phosphate Derivatives

Field of the invention

The invention relates to complexes of phosphate derivatives. More particularly the invention relates to complexes of phosphate derivatives of hydroxylated active compounds.

5 Background of the invention

In this specification, where a document, act or item of knowledge is referred to or discussed, this reference or discussion is not to be taken as an admission that the document, act or item of knowledge was at the priority date:

- (a) part of common general knowledge; or
- 10 (b) known to be relevant to an attempt to solve any problem with which this specification is concerned.

Over the past century, quantitative structure activity relationships (QSAR) have evolved and predominated in medicinal chemistry research programs. QSAR methods generate mathematical models to describe biological function of drug formulations. Deriving a 15 mathematical description of biological activity is characterized by two assumptions with respect to the relationship between the chemical structure and the biological potency of a compound. The first is that one can transform the chemical structure of a compound into numerical descriptors relevant to biological activity of a compound. The second establishes a quantitative relationship between these mathematical descriptors and potential 20 biological activity.

The mathematical descriptors are usually either physiochemical, such as pKa or partition coefficient, or substructural, such as the presence or absence of functional groups, e.g. CO₂R or SH, and assist the formulating chemist to improve the solubility of the biologically active compound.

25 This is recognized to revolve around fundamental strategies aimed to increase solubility and dissolution rate of drugs derived from dosage forms. Theoretically, these strategies make the drug more available for absorption, and involve techniques such as co-solvent addition, solid state manipulation and pro-drug modification.

Lipids as carriers

A number of drugs are more lipid soluble rather than water soluble, therefore lipids have been the carrier of choice for such drugs. Lipids are selected as drug vehicles based on their digestibility. Surfactant and co-solvent addition can facilitate digestion by increasing 5 solubilization within the intestine and formation of chylomicrons/VLDL by the enterocyte to improve lymphatic transport.

Lipid-based formulations, in particular, self-emulsifying drug delivery systems (SEDDS) and self micro-emulsifying drug delivery systems (SMEDDS) which utilize isotropic mixtures of triglyceride oils, non- surfactants and drugs, have been shown to overcome 10 some of the barriers resulting in improved absorption characteristics and more reproducible plasma profiles of selected drugs.

SEDDS and SMEDDS can be filled into either soft or hard gelatine capsules, allowing rapid emulsification following release of the capsule contents and exposure to gentle agitation in an aqueous media. Following emulsification, the fine oil droplets (< 5 μm in 15 diameter) empty rapidly from the stomach and promote wide distribution of the lipophilic drug throughout the gastrointestinal tract. This fine droplet distribution increases surface area for the drug to partition into the intestine and should theoretically improve absorption.

Derivatisation

Another strategy to improve solubility is to derivatise the compound, also known as 20 forming pro-drugs. A number of undesirable properties may preclude the use of potentially valuable drug drugs in clinical practice. Derivatisation has long been recognized as an important means of increasing efficacy and bioavailability of such drugs. Pro-drugs may be of limited value unless the pro-drug displays adequate stability, solubility, permeability and capability to revert to the parent compound once absorbed into 25 the systemic circulation.

For example, one earlier attempt to address this problem involved forming covalent bonds with sugars and polyalcohols. However, further problems were created as the additional substituent must then be removed before drug activity is regenerated. For example, tocopherol polyethylene glycol succinate (TPGS) is being sold as a water soluble 30 derivative of α -tocopherol. There are indications that this derivative is absorbed even when bile secretion is impaired however, the issue of hydrolysis of the ester linkage to

succinate and metabolism of the resulting polyethylene glycol 1000 does not seem to have been addressed. It has not been established if and when the ester group hydrolyses. If the ester group does not hydrolyse then the tocopherol is not released and cannot act on the body. If the ester is hydrolysed then the next issue is whether the body can metabolise the 5 polyethylene glycol by-product and dispose of it. If the body cannot metabolise the by-product then there could be a build up of by-product leading to side-effects. The TPGS product is also inconvenient and difficult to utilize clinically.

Limitations of current drug solubilisation strategies

Today, QSAR remains a useful tool to help discover, quantify and evaluate possible 10 biological activity. However, QSAR has been criticized for not being able to effectively generate descriptors for three dimensional features, such as hydrophobicity and some electronic effects of drug interaction including hydrogen bonding. QSAR is also known to be inadequate in relation to describing various biological processes including gastrointestinal absorption, distribution, metabolism and excretion.

15 Development of lipid formulation strategies have also been helpful but only based upon the assumption that important biologically active compounds are passively absorbed and providing a dissolution gradient will improve absorption. This assumption is flawed and does not account for the possibility of active absorption. This delivery strategy therefore remains limited and cannot account for the fact that even after optimal formulation, 20 absorption of poorly soluble nutrients from food is higher.

While ester derivatisation and solubilistion in SEDDS are known to improve lymphatic transport by the notion of forming small lipidic artificial chylomicrons, the methods are inefficient and probably more important to permit metabolism, rather than increasing transport of intact lipidic microstructures recognisable by transfer proteins. The use of 25 alternative historic formulation strategies may therefore even restrict clinical utility of α -tocopherol and result in reduced efficacy.

Example of the limitations of QSAR formulation approaches

Tocopherol (vitamin E) is a poorly absorbed, lipid soluble vitamin and chemically unstable due to oxidation of the phenolic group. The majority of natural tocopherol is currently 30 extracted from soy oil distillate and presented as simple substituted esters - either succinate or acetate derivatives. While this is primarily undertaken to prevent oxidation of the

phenolic group and enhance stability, derivatisation is also thought to improve lymphatic transport. There have been a number of attempts to enhance α -tocopherol acetate lymphatic transport via lipid formulation approaches. However despite some improvement, the extent of α -tocopheryl ester absorption after oral supplement 5 administration is still poor and subject to large inter-patient variation. In contrast, dietary intake of vitamin E may result in a rapid and parallel increase in the content of α -tocopherol in blood plasma and erythrocytes.

Other drugs and nutrients are also subject to poor and variable absorption properties following current oral formulation strategies including phenytoin, vitamin A and CoQ₁₀, 10 suggesting that physio-chemical factors other than dispersion, digestion and solubilisation control their bioavailability.

Transportation

In recent years it has become apparent that absorption across biological membranes of some pharmacologically active compounds eg: drugs and nutrients (vitamin E, ubiquinone, 15 etc.) , and endogenously important compounds such as phospholipids may be the limiting factor for bioavailability. As suggested such biological processes are difficult to describe mathematically as they are often multi dimensional. It is therefore proposed that gastrointestinal uptake and transport of many biologically active compounds is dependent on other transportation mechanisms.

20 Studies have shown that α -tocopherol phosphate is an effective antioxidant and capable of preventing hypoxanthine/xanthine oxidase induced oxidative damage. α -tocopherol phosphate is more water soluble than tocopherol or its succinate esters. These studies indicate that α -tocopherol phosphate not only improves chylomicron formation but also improves tissue penetration.

25 The art of efficient drug delivery therefore requires that the drug be not only soluble in the aqueous biological medium but in an appropriate form to permit transport of either individual drug molecules or very small aggregates of the drug molecules. This aim may be difficult to realize with drugs that are lipid soluble and not significantly water soluble. Such drug molecules have hydrophobic regions that form large aggregates in the high 30 dielectric constant water rich medium where transport occurs. As a result, there have been

investigations to discover a drug delivery system which increases the water solubility of the drugs.

Unpublished international patent application no PCT/AU00/00452 teaches the formation of phosphorylated complex alcohols in conditions which preserve the complex alcohols.

5 These complex alcohols include hormones, phytosterols, tocopherols (chromans), vitamin K1 and other oil-soluble vitamins and dietary supplements as well as drug compounds such as amoxycillin. These phosphorylated complex alcohols are more water soluble than the complex alcohols themselves, but it is desirable to achieve a yet higher level of bioavailability.

10 In summary, effective delivery of poorly water soluble compounds should not only provide delivery to the intestinal wall but also promote transport through it. There is need for a drug delivery system that embraces these concepts.

Whilst the following discussion concerns tocopherol, it is also to be understood that the same principles apply to any drug hydroxy compounds.

15 Tocopherol

Vitamin E (tocopherol) is an essential part of skin dynamics and is known to be very important for skin health, with deficiency manifesting as a cornified, scaly delicate skin, thickened epidermis, scaling, lesions, chronic infection, inflammation and erythema. Vitamin E is the main naturally occurring lipid soluble agent protecting the skin from 20 stress, and is the main lipid soluble agent protecting the cell membrane lipids from peroxidation.

Skin is subject to constant stress due to exposure to everyday elements – sun, wind and water. As a result, it is common for many cosmetic products such as lotions, moisturizers, shampoo and conditioners to contain vitamin E to assist in maintaining skin health and/or 25 mitigate and/or prevent hair and skin damage resulting from ultraviolet radiation and other environmentally produced free radicals. In order to assist in maintaining skin health, it is necessary for the vitamin E to reach the target area of the dermis. The most direct method of achieving this targeting is to apply a topical formulation to the affected area. However, topical application of vitamin E to the skin using current formulations has variable success 30 due to the skin's ability to erect an impenetrable barrier to many outside elements. It is critical to provide for the penetration of vitamin E through the epidermis to the dermis.

It is believed that topical formulations using tocopherol acetate have not been able to deliver adequate tocopherol beyond the epidermal layers, and therefore provide little benefit. Since tocopheryl acetate is a lipidic material requiring formulation with an oil in water emulsion, absorption from such a formulation is less than optimal.

5 The more bioactive salts of tocopheryl phosphate are beginning to also be used by cosmetic formulators. The product produced by known phosphorylation processes is a mixture of mono-tocopheryl phosphate (TP), di-tocopheryl phosphate (T2P), mono-tocopheryl di-phosphate (TP2) and di-tocopheryl pyrophosphate (T2P2). TP is the desired product of known phosphorylation processes as it is hydrophilic. Some unreacted 10 tocopherol (T) is also formed when T2P, TP2 and T2P2 are hydrolyzed to produce more of the desired hydrophilic component TP.

Before the mixture may be used in cosmetic applications, the water solubility must be increased. T2P has poor water solubility and is therefore removed or modified in the prior art. This is time consuming, costly and, unless a proper solvent is chosen, can result in 15 undesirable solvent residues.

Formulation properties

Cosmetic products must also be aesthetic and pleasant to use. Of course, the products must be compatible with eye, skin and oral mucosa and have an overall toxicity profile appropriate for topical application. Applications which are designed for the oral mucosa 20 and/or lip care must also be of an acceptable taste. If tocopheryl phosphates are to be used as a source of Vitamin E in foaming and cleansing products, then the hydrophobic substances need to be removed or modified to mitigate their foam suppression properties. Consumers have started to prefer transparent creams, lotions and gel vehicles for use on skin and hair, particularly for infant care, as this is a symbol of purity and mildness. 25 Current tocopheryl phosphates cannot be used in such transparent products because they have limited water solubility and form opaque emulsions.

Finally, the opaque creams and lotions made with current tocopheryl phosphate mixtures have considerable stability problems at elevated temperatures and temperatures below freezing because of the limited water solubility of the tocopheryl phosphates.

30 There is thus a need for a drug delivery system which provides improved bioavailability and/or improved formulation properties.

Summary of the invention

In this specification, the term "hydroxylated active" refers to chemical substances having hydroxy groups which may be phosphorylated and (in the non-phosphorylated form) have a desired activity. The term "hydroxylated active" includes, but is not limited to, drugs, 5 vitamins, phytochemicals, cosmeceuticals, nutraceuticals and other health supplements. The hydroxylated active may be administered through oral, topical, inhalation, ophthalmic, intravenous, enteral, parenteral or other appropriate presentations including those commercially utilized.

The present invention relates to the discovery that the reaction product of one or more phosphate derivatives of a hydroxylated active and a complexing agent selected from amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids has useful properties. 10

According to the invention there is provided a composition comprising the reaction product of:

15 (a) one or more phosphate derivatives of one or more hydroxylated actives; and
(b) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.

Preferably, the mole ratio of phosphate derivatives of one or more hydroxylated actives to 20 complexing agents is in the range of from 1:10 to 10:1. Preferably, the mole ratio of phosphate derivatives of one or more hydroxylated actives to complexing agents is in the range of from 1:2 to 2:1. A person skilled in the art will understand that the resultant composition will be a mixture of complexed and non-complexed phosphate derivatives of hydroxylated actives depending on the amount of complexing agent used.

25 In a preferred embodiment there is provided a therapeutic formulation comprising (i) the reaction product of (a) and (b); and (ii) an acceptable carrier.

According to a second aspect of the invention, there is provided a method for improving the bioavailability of a hydroxylated active comprising the step of reacting:

30 (a) one or more phosphate derivatives of one or more hydroxylated actives;
with

(b) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.

Preferably, there is a further step of adding an acceptable carrier.

5 There is also provided a method for administering to a subject a therapeutic formulation with an effective amount of one or more hydroxylated actives comprising administering to the subject a therapeutic formulation comprising:

(a) an effective amount of the reaction product of:

10 (i) one or more phosphate derivatives of one or more hydroxylated actives; and

(ii) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids; and

15 (b) an acceptable carrier.

The complexing agents increase the hydrophilic region on the hydroxylated active to one that is of relatively high electronic charge and attractive to water molecules (more water soluble) which may cause the resulting complexes to be more bioavailable than the parent hydroxylated active. This is possible due to delivery of a complex in the proximity of the 20 intestinal wall in a derivative form which may result in efficient transport and higher tissue penetration. Further, the new complexes are weakly dissociated by water back to the original components of the complex thus releasing the drug, and the process does not require enzyme action or any other reaction to release the hydroxylated active.

Complexation acts to convert lipids to surfactants allowing better emulsification of the 25 active compound. There are a number of situations where complexation may be of value in the drug industry. Complexation may allow conversion of some injectable only formulations to orally available products by improving solubility. Complexation may also decrease injection time, increase predictability of bioavailability and allow further development of compounds whose low bioavailability has previously restricted clinical 30 use.

In a preferred embodiment, the one or more hydroxylated actives are electron transfer agents. Preferably, one of the electron transfer agents is tocopherol. It has been found that complexes of tocopheryl phosphates can be formed which are more soluble in water than the parent tocopheryl phosphates. Further, it is not necessary to remove any T2P prior to 5 forming these complexes. As these complexes of tocopheryl phosphate are more hydrophilic, they are useful for cosmetic formulations. Phosphorylated tocopherol complexed with a tertiary amine acts as both a surfactant and active source of vitamin E, achieving higher bioavailability by quickly reaching the rate limiting CMC because of its higher water solubility or ability to form better emulsions and eventually chylomicrons if 10 used in an oral or injectable formulation.

DETAILED DESCRIPTION

The following terms are used throughout the specification and are intended to have the following meanings:

The term "hydroxylated active" as defined above. Examples of hydroxylated actives 15 include but are not limited to:

1. electron transfer agents (as defined below)
2. narcotic analgesics such as morphine and levorphanol,
3. non narcotic analgesics such as codeine and acetaminophen,
4. corticosteroids such as cortisone,
- 20 5. anaesthetics such as propofol,
6. antiemetics such as scopolamine,
7. sympathomimetic drugs such as adrenaline and dopamine,
8. antiepileptic drugs such as fosphenytoin,
9. anti-inflammatory drugs such as ibuprofen,
- 25 10. thyroid hormones and antithyroid drugs including thyroxine,
11. phytochemicals including α -bisabolol, eugenol, silybin, soy isoflavones,
12. iridoid glycosides including aucubin and catalpol,
13. sesquiterpene lactones including pseudoguaianolide from Arnica chamissonis,

14. terpenes including rosmarinic acid and rosmanol,
15. phenolic glycosides including the salicylates salicin, saligenin and salicyclic acid,
16. triterpenes taxasterol or α -lactucerol, and isolactucerol,
17. *p*-hydroxyphenylacetic acid derivative taraxacoside,
- 5 18. hydroquinone derivatives including arbutin,
19. phenylalkanones including gingerols and shagaols,
20. hypercin, and
21. acylphloroglucides including xanthohumol, lupulone, humulone and 2-methylbut-3-en-2-ol.

10 The term "electron transfer agent" is used herein to refer to the class of hydroxylated actives which (in the non-phosphorylated form) can accept an electron to generate a relatively stable molecular radical or accept two electrons to allow the compound to participate in a reversible redox system. Examples of classes of electron transfer agents that may be phosphorylated include hydroxy chromans including alpha, beta and gamma 15 tocols (eg tocopherol) and tocotrienols in enantiomeric and racemic forms; quinols being the reduced forms of vitamin K1 and ubiquinone; hydroxy carotenoids including retinol; calciferol and ascorbic acid.

The term "effective amount" is used herein to refer to an amount that reaches the target site in the human or animal in an amount that is measurably effective in the reduction of one or 20 more symptoms.

The term "acceptable carrier" is used herein to refer to a carrier considered by those skilled in the drug, food or cosmetic arts to be non-toxic when used to treat humans, animals or plant in parenteral or enteral formulations. For example, ingestible compositions may include phospholipids such as lecithin, cephalins and related compounds.

25 The "phosphate derivatives of hydroxylated actives" comprise compounds covalently bound by means of an oxygen to the phosphorus atom of a phosphate group. The oxygen atom is typically derived from a hydroxyl group on the electron transfer agents. The phosphate derivative may exist in the form of a free phosphate acid, a salt thereof, a di-phosphate ester thereby including two molecules of electron transfer agent, a mixed ester 30 including two different compounds selected from electron transfer agents, a phosphatidyl


compound wherein the free phosphate oxygen forms a bond with an alkyl or substituted alkyl group. For example, tocopheryl phosphate may be provided mixed with ascorbyl phosphate or as an ascorbyl/tocopheryl phosphate. Similarly, ascorbyl phosphates may be combined with tocotrienol phosphates and/or ubiquinol phosphates. Similarly, retinyl phosphate could be combined with tocopheryl phosphates and/or ascorbyl phosphates.

5 Phosphorylation may be accomplished by any suitable method. Preferably, the hydroxyl group in the hydroxylated active is phosphorylated using P_4O_{10} according to the method in international patent application no PCT/AU00/00452. Excess diphosphate derivatives may be hydrolyzed using methods known to those skilled in the art

10 10 Complexing agents may be selected from alkyl amino/amido betaines, sultaines, phosphobetaines, phosphitaines, imidazolium and straight chain mono and dicarboxy amphotolytes, quaternary ammonium salts, and cationic alkoxylated mono and di-fatty amines, and amino acids having nitrogen functional groups and proteins rich in these amino acids. A preferred complexing agent is N-lauryl imino di-propionate.

15 15 The amino acids having nitrogen functional groups include glycine, arginine, lysine and histidine. Proteins rich in these amino acids may also be used as complexing agents, for example, casein. These complexing agents are used when the composition needs to be ingestible.

20 20 The amphoteric surfactants may be amphotolytic surfactants, that is, they exhibit a pronounced isoelectric point within a specific pH range; or zwitterionic surfactants, that is, they are cationic over the entire pH range and do not usually exhibit a pronounced isoelectric point. Examples of these amphoteric surfactants are tertiary substituted amines, such as those according to the following formula:



25 25 wherein R^1 is chosen from the group comprising R^4 or R^4CO wherein R^4 is straight or branched chain mixed alkyl radicals from C6 to C22.

30 30 R^2 and R^3 are either both R^5 or one R^5 and one H wherein R^5 is chosen from the group comprising CH_2COOX , $CH_2CHOHCH_2SO_3X$, $CH_2CHOHCH_2OPO_3X$, CH_2CH_2COOX , CH_2COOX , $CH_2CH_2CHOHCH_2SO_3X$ or $CH_2CH_2CHOHCH_2OPO_3X$ and X is H, Na, K or alkanolamine.

.....

WO 02/40034

PCT/AU01/01476

12

In addition, when R¹ is RCO then R² may be (CH₃) and R³ may be (CH₂CH₂)N(C₂H₄OH)-H₂CH₂OPO₃Na or R² and R³ together may be N(CH₂)₂N(C₂H₄OH)CH₂COOH.

Commercial examples are DERIPHAT sold by Henkel/Cognis, DEHYTON sold by Henkel/Cognis, TEGOBETAINE sold by Goldschmidt and MIRANOL sold by Rhone 5 Poulen.

Cationic surfactants, such as quaternary ammonium compounds, will also form complexes with phosphorylated derivatives of drug hydroxy compounds such as tocopheryl phosphates. Examples of cationic surfactants include the following:

- (a) RN⁺(CH₃)₃ Cl⁻
- 10 (b) [R₂N⁺CH₃]₂ SO₄²⁻
- (c) [RCON(CH₃)CH₂CH₂CH₂N⁺(CH₃)₂C₂H₄OH]₂ SO₄²⁻
- (d) Ethomeens: RN[(CH₂CH₂O)_x CH₂OH][(CH₂CH₂O)_y CH₂OH] wherein x and y are integers from 1 to 50.

wherein R is C8 to C22 straight or branched chain alkyl groups or mixed alkyl groups.

15 Silicone surfactants including hydrophilic and hydrophobic functionality may also be used, for example, dimethicone PG betaine, amodimethicone or trimethylsilylamodimethicone. For example, ABILE 9950 from Goldschmidt Chemical Co. The hydrophobe can be a C6 to C22 straight -or branched alkyl or mixed alkyl including fluoroalkyl, fluorosilicone and or mixtures thereof. The hydrophilic portion can be an alkali metal, alkaline earth or 20 alkanolamine salts of carboxy alkyl groups or sulfoxy alkyl groups, that is sultaines, phosphitaines or phosphobetaines or mixtures thereof.

These complexes may be formed by the reaction of one or more phosphate derivatives of one or more hydroxylated actives and one or more complexing agents selected from the group consisting of amphoteric surfactants and cationic surfactants. Complexes of 25 phosphate derivatives of hydroxylated actives can be made by neutralization of the free phosphoric acid ester directly during manufacture as a raw material suitable for compounding or in-situ blending of the mixed sodium salts with the complexing agents during the finished cosmetic formulation process.

Formulations according to the present invention may contain from about 0.5 to about 30 weight percent hydroxylated active phosphate derivative complexes, preferably from about 1 to about 20 wt percent, more preferably about 2 to about 15 wt percent, and most preferably about 3 to about 12 wt percent, based on the total weight of the composition. A 5 most preferred amount of hydroxylated active phosphate derivative complexes is about 5 to about 10 wt. %.

Complexes of tocopheryl phosphate are particularly preferred electron transfer agent phosphate complexes useful in the present invention. The tocopheryl phosphate product produced by known phosphorylation processes is a mixture of mono-tocopheryl phosphate 10 (TP), di-tocopheryl phosphate (T2P), mono-tocopheryl di-phosphate (TP2) and di-tocopheryl pyrophosphate (T2P2). The preferred result is usually a mixture of about 70/30 TP to T2P, however this results in limited water solubility. Before the mixture may be used in cosmetic applications, the water solubility must be increased by forming complexes according to the invention.

15 Consumers have started to prefer transparent creams, lotions and gel vehicles for use on skin and hair, particularly for infant care, as this is a symbol of purity and mildness. Tocopheryl phosphates available prior to the present development could not be used in such transparent products because they have limited water solubility and form opaque emulsions. Finally, the opaque creams and lotions made with such prior tocopheryl 20 phosphate mixtures have considerable stability problems at elevated temperatures and temperatures below freezing because of the limited water solubility of the tocopheryl phosphates.

The hydroxylated actives phosphate derivative complexes are water-soluble and thus 25 enhance the incorporation of the hydroxylated actives into water-based drug and cosmetic formulations. The water solubility of the complexes also increases the stability of the formulations over a wide range of temperatures and permits that manufacture of clear or transparent solutions. It has also been found that the complexes have increased surface 30 activity and exhibit good foaming properties. This makes the complexes useful for cosmetic products such as cleansing agents and shampoo. The complexes provide stable cosmetic products, which are consumer acceptable while minimizing the problems with current hydroxylated active formulations.

14

Hydroxylated actives phosphate derivative complexes may be used in various products including antiperspirant sticks, deodorant sticks, sunscreens, facial cleansers, make-up removers, hair pomades, facial gels, oil in water moisturizers, lotions, conditioners, shampoos, conditioning shampoos, toothpaste, and foaming body washes.

5 The formulation or method of the invention may also be delivered in any suitable drug delivery system applied to the dermis including patches, gels, depots, plasters, aerosols and other sustained or delayed release systems designed to alter absorption kinetics.

A person skilled in the art will know what components may be used as the acceptable carrier for the compositions of the present invention. These will include excipients such as 10 solvents, surfactants, emollients, preservatives, colorants, fragrances and the like.

There is also provided a method for increasing the water solubility and/or detergent properties of tocopheryl phosphate derivatives comprising the step of reacting phosphorylated tocopherol with one or more complexing agents selected from the group consisting of amphoteric surfactants and cationic surfactants.

15 **Examples**

The invention will now be further explained and illustrated by reference to the following non-limiting examples.

The following components were used in the examples.

Brij 72	POE 2 Stearyl Ether ex Unichema Americas
Brij 721	POE 21 Stearyl Ether ex ICI or Uniqema Americas
Carbopol 934 25%	Ex BF Goodrich
Cetiol LC	Ex Henkel/Cognis
Cetiol V	Ex Henkel/Cognis
Cetiol 3600	Ex Henkel/Cognis
Citric acid	Ex Henkel/Cognis
Cocamide mea	Ex Croda
Cocamidopropylbetaine	35% commercial formulation called Velvetex BA 35 ex

Dehyquart F	cationic conditioner ex Henkel/Cognis
Deriphat 160	a 97% free flowing powder of lauryl-imino-dipropionate ex Henkel/Cognis
Di-sodium-N-lauryl beta imino dipropionate	Ex Henkel/Cognis
Drakeol 9	LT Mineral Oil ex Penreco
Emerest 132	Stearic Acid ex Cognis
Emerest 2400	Ex Henkel/Cognis
Emerest 2314	Ex Henkel/Cognis
Emulgin B2	Ex Henkel/Cognis
Germaben II	Preservative ex Sutton Labs
Glycerin	Ex Henkel/Cognis
Isostearyl imidazoline	Miranol BM ex Rhone Poulenc
Kathon CG	Ex Rohm & Haas
Lanette O	Ex Henkel/Cognis
Lauramide mea	100% commercial formulation called Standamide mea ex Henkel/Cognis
Microfine TiO ₂	Ex Tayca Corp
Mixed waxes	Carnube, paraffin, beeswax ex Croda
Natrasol 250 HHR	Ex Hercules
Oils emollients	Ex Croda
Pelemol PDD	Propylene Glycol Dicaprylate/ Dicaprate ex Phoenix
Peppermint Oil	Ex Firmenich
P ₄ O ₁₀	Ex China
Red iron oxide	Ex Warner Jenkinson
Silicones	polydimethylsiloxane polymers ex Dow Corning

WO 02/40034

PCT/AU01/01476

16

Sodium lauryl 2 ether sulfate	50% commercial formulation called Standapol ES 250 ex Henkel/Cognis
Sodium lauryl-3-ether sulfate	Ex Henkel/Cognis
Stearyl alcohol	Ex Croda
Tocopherol	Ex Hoffman La-Roche
Triethanolamine	Ex Henkel/Cognis

Example 1

Complexes of tocopheryl phosphates with ampholytic surfactant are prepared (Complex A).

5 Tocopherol was treated with P_4O_{10} as outlined in PCT/AU00/00452 followed by hydrolysis of T_2P_2 . The resultant tocopheryl phosphate mixture was reacted with an equimolar amount of di-sodium-N-lauryl beta imino dipropionate. The water content was adjusted to form viscous slurry of about 30-70 % wt/wt total solids. The pH was adjusted to 6.0-6.5 using either citric acid or additional beta imino surfactant. The slurry can be 10 dried to the desired active concentration as slurry or as a powder via any conventional drying process i.e. oven-tray-drier and ground via fitzmill to desired particle size. The finished product was a free flowing white to off white powder or aqueous slurry, either of which was dispersible in water.

Example 2

15 Complexes of tocopheryl phosphates with a zwitter-ionic surfactant were prepared from sodium salts of tocopheryl phosphates (Complex B). The sodium salts of tocopheryl phosphate, the zwitterionic surfactant and Complex B were tested for foaming properties using the hand lather test.

Part A: preparation of sodium salts of tocopheryl phosphates

20 The tocopherol was treated with P_4O_{10} as outlined in PCT/AU00/00452 followed by hydrolysis of T_2P_2 . After hydrolysis, the tocopheryl phosphates were neutralized to the

mono- and di-sodium salts. The resulting product was a viscous tan paste with a Gardiner color of about 8-10 and a pH of 8.0-8.5.

A 2% wt/wt aqueous solution of this paste formed an emulsion with a particle size of at least 10 microns (milky), which produced little or no foam as per hand lathering tests. The 5 emulsion was unstable after two days at 50°C and after one week at ambient room temperature.

Part B: -preparation of Complex B

Forty parts of the tocopheryl phosphates paste formed in part A were mixed with 60 parts of cocamidopropylbetaine containing sufficient water to form a 40% wt/wt slurry using a 10 Waring blender. The weight ratio of betaine to tocopheryl phosphate was 1.5:1. The pH was adjusted to 6.0-6.5 using citric acid.

A 5% active solution containing 40% tocopheryl phosphate (equivalent to the 2% wt/wt solution prepared in part A) formed a translucent emulsion with particles of less than 2 microns, which produced copious foam via hand lathering, tests. This foam was denser 15 than the foam produced by either the cocamidopropylbetaine or the tocopheryl phosphates from part A alone. The hand lathering tests showed that a residual amount of the product provided a tactile skin feel - an indication of adherence to skin and keratin fiber.

Properties

Appearance	a translucent emulsion
pH as is	6.0-6.5
Lather	Copious foam
Stability 50°C	Stable and clear at least one week

20 **Example 3**

In this example, complexes were dry blended. Certain complexes can also be dry blended prior to either forming slurry or compounding in-situ.

Forty parts of mixed sodium salts of tocopheryl phosphates were ground to a powder via freeze drying and mixed in a Waring blender with sixty parts of Deriphat 160 a 97% free

flowing powder) for twenty minutes to form a homogeneous free flowing powder consisting of di-sodium lauryl-imino-dipropionate tocopheryl phosphate complexes.

Example 4

In this example, a hand and body wash was formulated using Complex A from Example 1

5 The tocopheryl phosphate salts were heated with water until clear and homogeneous. Ammonium lauryl sulfate was added and mixed until clear. Cocamide Mea was added and the pH adjusted to 5.5 to 6.0 with citric acid. The solution was cooled to 35°C and Kathon CG added and mixed for ten minutes. Deionized water was added to complete the finished product to 100 parts total. Sodium chloride was added to adjust viscosity to 4000-5000 10 centipoises at 25°C.

Ingredient	%wt/wt
Complex A from Example 1	10
Ammonium lauryl sulfate 30%	40
Cocamide mea	2
Kathon cg	0.05
NaCl, citric acid, deionized water	qs to 100%

Properties	
Viscosity at 25°C	4000-5000
pH as is	5.5 to 6.0

Example 5

A foaming shower gel for skin/hair for sports and chlorine scavenging was formulated 15 using Complex B from Example 2.

Fifteen parts of the 40% Complex B from Example 2 were mixed with fifty parts of water and heated to 50°C and mixed until clear and homogeneous. Thirty parts of 30% active sodium lauryl-3-ether sulfate were added and mixed until the solution was clear and homogeneous. Three parts of cocamide mea were added and the pH adjusted to 6-6.5 with

WO 02/40034

PCT/AU01/01476

19

lactic acid followed by cooling to 35°C. 0.1 parts of preservative kathon cg 0.2 were added followed by deionized water to 100% total to give the following formula:

Ingredient	% Wt/wt
Complex B from Example 2 (40%)	15
Sodium lauryl-3-ether sulfate	35
Cocamide mea	3
Preservative, color, fragrance, deionized water	Qs to 100%
<hr/>	
Properties	
Viscosity	25,000 cps
pH as is @ 25°C	6.0—6.5

5 The complex can also be made in-situ while compounding the finished cosmetic.

Example 6

A sports shampoo and shower gel was prepared with in-situ formation of the tocopheryl phosphate complexes.

10 Sixty parts of deionized water were heated to 60-70°C followed by the addition of seven parts of 35% cocamidobetaine and mixed until clear. Two parts of mixed sodium salts of tocopheryl phosphate were added and mixed until clear and homogeneous. Twenty-five parts of 50% sodium lauryl 2 ether sulfate were added and mixed until solution was clear. Three parts of cocamide mea were added and mixed until clear. The pH was adjusted to 5.0-5.5 with citric acid and cooled to 35°C. The preservative, color and fragrance were 15 added and the batch adjusted to 100 % with deionized water to provide the following formula.

Ingredient	% wt/wt
------------	---------

WO 02/40034

PCT/AU01/01476

20

Ingredient	% wt/wt
Sodium lauryl 2 ether sulfate	25
Cocamidopropylbetaine	7
Sodium tocopheryl phosphates	2
Lauramide mea	3
Citric acid	Qs
Preservative and deionized water	Qs to 100%

Properties	
Appearance	clear viscous gel
viscosity	25,000 cps
pH as is	5.0-6.0
Lather	rich lubricious
Stability 50°C	Stable and clear for 2 weeks
Freeze/Thaw: 2 cycles	Stable

The gels of this type often require a rheology modification using semi-synthetic polymers such as cellulosic gums as needed.

Example 7

5 An economy conditioning shampoo was prepared from the formulation in Example 6.

The product from Example 6 was diluted with deionized water at a wt/wt ratio of 75 parts of Example 6 to twenty five parts of water to provide a shampoo with a viscosity of 3000 cps at 25°C. The product was clear and stable as per Example 6. The product is high foaming/cleansing with the additional benefit of providing perceived body or fullness to hair.

10 Applications of the complex salts designed for non-foaming areas such as hair conditioners, body and facial creams, sun, shave and lip products etc can be produced via using a higher alkyl chain as the hydrophobic group on the amphoteric portion of the

complex and/or the use of cationic salts such as those used in hair conditioners. These products can be made using any of the above methods of complex formation.

Example 8

A rinse-off hair conditioner was prepared using tocopheryl phosphates with a cationic 5 surfactant to form a complex.

Ingredient	% wt/wt
Dehyquart F	2
Tocopheryl phosphates	2
Stearyl alcohol	1
Brij 721	2
Natrasol 250 HHR	1
Citric acid	0.5
Preservative, dye and deionized water	Qs to 100%

Properties	
Appearance	clear viscous gel
Viscosity	5000 cps
pH as is	4-5
Lather	rich lubricious
Stability 50°C	Stable for 2 weeks
Freeze/Thaw - 2 cycles	Stable

Example 9

A facial anti aging crème was prepared using an isostearyl analogue of imidazoline (amphoteric surfactant).

WO 02/40034

PCT/AU01/01476

22

Ingredient	% wt/wt
Part A	
Isostearyl imidazoline	1.0
Emulgin B2	1.4
Emerest 2400	2.0
Lanette O	2.0
Emerest 2314	5.0
Cetiol LC	3.5
Cetiol V	3.5
Cetiol 3600	3.0
Part B	
Carbopol 934 (25%)	10.0
Tocopheryl phosphate	2.0
Deionized water	57.6
Glycerin	5.0
Part C	
Triethanolamine	0.5
Part D	
Germaben II preservative	1.0

Mix parts A and B in separate vessels and heat to 80°C. Add A to B and mix at 80°C for 10 minutes. Cool to 60°C then add C. Cool to 60°C then add D.

WO 02/40034

PCT/AU01/01476

23

Properties

Appearance	stable white crème with pleasant tactile skin feel
Stability 50°C	Stable for 1 month
Freeze/Thaw - 2 cycles	Stable

Example 10

A lanolin free lipstick was prepared using the complex in Example 9.

Ingredient	% wt/wt
Isostearyl imidazolinium tocopheryl phosphate	3
Mixed waxes	30
Oils emollients	45
Red iron oxide	5
Microfine TiO ₂	5
Silicones	as to 100%

5 Stable lipstick with good pay-off and pleasant taste.

Example 14

A lotion was prepared as follows. The following ingredients are mixed.

Ingredient	w/w percent
cetyl alcohol	0.75
C12-15 alcohols benzoate	5
butylated hydroxyanisole	0.1
PEG-100 stearate	0.25
water, deionized or distilled	70.4
propylene glycol	3.0
tocopheryl phosphate complex (TPC of Ex. 2)	10.5
acetone	10.0

Example 15

5 A cream was manufactured by mixing the following ingredients:

Ingredients	w/w percent
cetyl-stearyl alcohol	1.25
C12-15 alcohol benzoate	5
butylated hydroxyanisole	0.01
PEG-100 stearate	0.85
water, deionized or distilled	69.1
propylene glycol	3
tocopheryl phosphate complex (TPC of Ex 1)	10.5
acetone	10

WO 02/40034

PCT/AU01/01476

25

Example 14

A gel according to the present invention was prepared by combining the following ingredients.

Ingredient	w/w percent
water, deionized or distilled	50.65
Veegum .RTM. (R.T. Vanderbilt Co.)	1.5
carboxy vinyl polymer (acid)	1
diisopropanolamine	0.75
ethyl alcohol, 200°	30.1
tocopheryl phosphate complex (TPC of Ex. 1)	15

5 **Example 15**

Fifteen mg of Carbomer (15 mg) was added to distilled water (495 mg) while stirring. Stirring was continued for about 45 minutes. A solution of sodium hydroxide (4.09 mg) in distilled water (4.9 ml) was added and stirring continued for 10 minutes. Ethyl alcohol (150 ml) and methyl salicylate (1 mg) were added to the stirred solution, followed by 10 tocopheryl phosphate complex (50% TP complex of Example 1--50% water) (400 mg), and distilled water (80 ml). The resulting mixture was stirred until a smooth gel was obtained.

Example 16

The following gel formulation was prepared according to the procedure described in Example 15.

Ingredient	w/w percent
tocopheryl phosphate complex	20
tetracycline	2
ethyl alcohol	20
PEG-8 caprate	6
colloidal mg aluminum silicate	2.5
hydroxyethylmethylcellulose	0.75
citric acid	0.05
water	Q.S.

5 **Example 17**

Aqueous gel compositions were prepared according to the following formulation:

Ingredient	w/w percent
tocopheryl phosphate complex	15
retin A	0.5
carbomer .RTM. 940	1
sodium hydroxide to desired pH	
water	QS

Example 18

A lotion with sunscreen was prepared as follows.

	Ingredients	%w/w
A	Brij 72 (POE 2 Stearyl Ether)	0.5
	Emerest 132 (Stearic Acid)	2.0
	Pelemol PDD (Propylene Glycol Dicaprylate/ Dicaprate)	10.0
	Drakeol 9 (LT Mineral Oil)	9.0
	Brij 721 (POE 21 Stearyl Ether)	1.0
	Octylmethoxy Cinnamate	7.0
	Benzophenane-3	2.0
	Dicorming 200 Fluid (Dimethicone)	1.0
B	Propyl Paraben	0.1
	Cabopol Ultrez 10 Slurry 3%	5.0
C	Water	10.0
	TEA 99%	1.2
	Water Distilled	10.0
	Methyl Paraben	0.25
	Lauryl Imino Dipropionic Acid Tocopheryl Phosphate - 40% with DMDMH	7.5
	Water Distilled q.s.	33.45

Heat A and C separately to 80°C. Add A to C while mixing with an homogenizer for 2 to 5 min. Remove the mixture from the homogenizer, add B (which has been heated to 70°C) and then cool to room temperature.

Example 19

A toothpaste was prepared as follows:

	Ingredients	% w/w
A	Sorbitol USP	15.0
	40% Lauryl Imino Dipropionic Acid	7.5
	Tocopheryl Phosphate	
B	Glycerin USP 96%	10.0
	Triclosan	0.3
	Na-Saccharin USP 40/60 Mesh	0.2
	Veegum D-Granular	2.0
	Peppermint Oil	1.1
	Stepanol WA/100 (Na-Lauryl Sulfate)	2.2
C	Veegum HF-6% (Ag/Al Silicate)	16.64
	Blue #1 FD+C (0.6%)	0.06
D	Na-CMC 7 H 5%	45.0

Mix together the components of A, then add all items of B to A and mix until uniform.

5 Add C and mix until uniform. Finally, add D slowly mixing until uniform.

Example 20

A tocopheryl phosphate amphoteric complex formulation is prepared as follows:

Ingredient	% w/w
di-sodium alpha tocopheryl phosphate N-lauryl imino dipropionate complex	30%
water	67%
lanolin creme	3%

Example 21

Di-sodium alpha tocopheryl phosphate N-lauryl imino dipropionate complex (a 60/40-N-lauryl imino dipropionate / mixed-phosphate weight ratio) was analyzed in tests as follows.

³¹P NMR

5 ³¹P spectra were carried out at ambient temperature using a Bruker DPX300 spectrometer. The complex mixture was dissolved in CDCl₃. The spectrum had a single peak at -2.9 ppm and a single peak at -7.9 ppm. There was also a small peak for inorganic phosphates at 1.0 ppm.

10 The spectrum for pure di-sodium mono-tocopheryl phosphate (dissolved in THF/H₂O (2:1)) consisted of a single peak at 1.1 ppm. The spectrum for pure sodium di-tocopheryl phosphate (dissolved in THF/H₂O (2:1)) consisted of a single peak at -7.5.

From this information it can be concluded that a mono-tocopheryl phosphate N-lauryl imino dipropionate complex formed and corresponds to the peak at -2.9 ppm.

Electrospray mass spectrometry

15 The complex product was then analysed by electrospray mass spectrometry on a Micromass Platform II spectrometer using an accelerating voltage of 40V. The spectrum had peaks at 328 for N-lauryl imino dipropionate, 509 for mono-tocopheryl phosphate, 838 for mono-tocopheryl phosphate N-lauryl imino dipropionate complex and 922 for di-tocopheryl phosphate.

20 The mono-tocopheryl phosphate N-lauryl imino dipropionate complex survived the intense accelerating field. A typical salt would dissociate in such an electron field therefore it is apparent that mono-tocopheryl phosphate N-lauryl imino dipropionate complex is not a typical salt.

Osmometry

25 A vapour pressure osmometer was used to investigate the dissociation of the di-sodium alpha tocopheryl phosphate N-lauryl imino dipropionate complex by comparing the lowering of the equilibrium temperature to give an identical partial pressure of water vapour around a drop of pure water versus various solutions as an indication of the relative moles of solute. The instrument does not output absolute temperature but instead gives an

WO 02/40034

PCT/AU01/01476

30

arbitrary scale that is directly related to sodium chloride as a solute, thus for 0.1M sodium chloride the output was a 29 unit effect.

N-lauryl imino dipropionate alone gives three ions and at 0.05M the effect was 38 units. If the complex was readily dissociated, then the additional tocopheryl phosphate would be 5 expected to increase the effect in the ratio 3:5 by the addition of the charged amino group as a cation and tocopheryl hydrogen phosphate anion. However, addition of 0.05M of tocopheryl phosphate to the 0.05M N-lauryl imino dipropionate resulted in a solution with 36 units.

This result demonstrates that the complex is not ionised in water therefore the complex was 10 not a typical salt where the ionic bonds are readily broken by high dielectric solvents such as water. The behaviour of the complex resembles potassium ferricyanide where the ferricyanide ion is not deemed to be a salt because the iron-cyanide bond is not broken by water as a solvent, such ions are called complexes.

Example 21

15 Di-sodium tocopheryl phosphate (1.3 g) was dissolved in 2 ml of water. Arginine hydrochloride (0.5 g) was added and the mixture was intimately mixed for one hour. The mixture increased in viscosity until a gel was formed indicating that a reaction had occurred.

20 The complex product was then analysed by electrospray mass spectrometry on a Micromass Platform II spectrometer using an accelerating voltage of 40V. The spectrum showed peaks at 510 (tocopheryl phosphate) and 683 (tocopheryl phosphate arginine complex) mass units. The 683 peak indicates the bond between arginine and tocopheryl phosphate survived the intense accelerating field and thus is very strong. A typical salt would not have survived such a field.

25 Example 22

Amoxycillin was treated with P_4O_{10} as outlined in PCT/AU00/00452 to prepare its phosphate derivatives. 445.4 g (1 mole) of amoxycillin phosphoric acid was dispersed in 2 L of water and 327.6 g of Deriphat added and mixed for 10 minutes to generate the complex. The solution was then dried to give the complex. The complex was shown to be 30 readily soluble in water.

Example 23

Timolol eye drops are utilized to decrease aqueous secretion from the ciliary epithelium and alleviate symptoms of open-angle glaucoma. Sterile ophthalmic drops containing 2.5 mg/ml of timolol can be mixed with 3 mg/ml hypromellose solution to reduce "stinging" 5 sensation and improve product absorption.

When 30 mg of timolol is mixed with phosphoric acid and excess fatty acid in sterile water, timolol phosphate is formed. Deriphat was added in an amount equimolar to the timolol phosphate was added and mixed for 10 minutes to form a complex which is more water soluble than the timolol hypromellose solution.

10 Example 24

Di-sodium ubiquinyl phosphate (0.3g) was dissolved in 2 ml of water. Deriphat (0.14g) was dissolved in 2 ml water and then added to the ubiquinyl phosphate mixture and intimately mixed for one hour. The mixture increased in viscosity until a gel formed indicating that a reaction had occurred.

15 The product was analyzed by electrospray mass spectrometry on a Micromass Platform II spectrometer using an accelerating voltage of 40V. The spectrum showed peaks at 945 (ubiquinyl phosphate) and 1273 (ubiquinyl phosphate N-lauryl imino dipropionate complex). The 1273 peak indicates the bond between N-lauryl imino dipropionate and ubiquinyl phosphate survived the intense accelerating field and thus is very strong. A 20 typical salt would not have survived such a field.

Example 25

The skin penetration properties of complexed and non-complexed tocopheryl phosphate (non-complexed (sodium salts)) were compared relative to tocopheryl acetate.

Test formulations

25 The test materials were made up on the basis of 5% mixed actives tocopherol (T), tocopheryl phosphate (TP) and tocopheryl diphosphate (T2P) or tocopheryl acetate in a vehicle consisting of 95/5 distilled water/ethanol with pH adjusted (if necessary to 6.5-7.0 with citric acid or dilute NaOH).

WO 02/40034

PCT/AU01/01476

32

Tocopheryl phosphate complexes (TPC)

The TPC used was lauryl-imino di-propionic acid tocopheryl phosphate; a surface-active amphoteric phosphate ester complex formed from lauryl imino propionic acid (Deriphat 160) and tocopheryl phosphates.

5

Active	TPC (micrograms per applied dose)
tocopheryl phosphate	188
di-tocopheryl phosphate	713
Tocopherol	20

The solution for TPC was based on 40% active mixed phosphates as the latter was reacted/combined in a 60/40-amphoteric/mixed-phosphate weight ratio (1.9-1 mole ratio). 12.5 w/w % of TPC was dissolved in 87.5 w/w % of the 95/5 water/ethanol mixture.

10 Di-sodium salt of mono and di-tocopheryl phosphates (DSS)

DSS was similar in TP and T2P content, however, unlike TPC, DSS existed as the mixed sodium salts. A slurry of 6.25 w/w % of 80% DSS in 93.75 w/w % of the 95/5-water/ethanol mixture iwa prepared.

Active	DSS (micrograms per applied dose)
tocopheryl phosphate	252
di-tocopheryl phosphate	1194
tocopherol	24

15

Tocopheryl Acetate (TA)

Tocopheryl acetate was obtained from Roche/BASF. 5.0 w/w % of TA was dispersed in 95.0 w/w % of 95/5 water/ethanol mixture.

WO 02/40034

PCT/AU01/01476

Method

The test formulations were evaluated in *in vitro* human skin penetration studies. Samples were analyzed for the mono- and di-tocopheryl phosphates, free alpha-tocopherol, and tocopheryl acetate by high performance liquid chromatography (HPLC). The tests were 5 conducted by DermTech International (San Diego, CA). Human cadaver skin was obtained and prepared. Each formulation was evaluated on triplicate sections from each donor at a topically applied dose of 5 $\mu\text{L}/\text{cm}^2$. Receptor solutions were collected over 48 hours at pre-selected time intervals. After 48 hours the skin surface was washed with isopropyl alcohol, and the skin was collected and split into epidermis and dermis. The skin sections 10 were extracted with isopropyl alcohol. All collected samples were processed and assayed for tocopherol, tocopheryl acetate, tocopheryl phosphate and di-tocopheryl phosphate.

15 Mass balance from the samples is between 80-120% of the applied dose. No tocopherols were observed in the receptor solution. This could be a result of amounts being below limits of detection, or degradation of the various tocopherol species into other, as yet uncharacterized, compounds.

Table 1: Skin Penetration Study

Percent Distribution of Tocopherols Recovered across Samples wt/wt %

DSS	T	TP	T2P
Surface Wash	65.05	41.40	56.05
Epidermis	26.74	47.06	37.31
Dermis	8.24	11.42	6.62
Dermis/Epidermis Ratio	0.31	0.24	0.18
TPC	T	TP	T2P
Surface Wash	50.00	48.82	70.92
Epidermis	35.99	24.55	16.67
Dermis	14.07	26.62	12.36
Dermis/Epidermis Ratio	0.39	1.08	0.74

TA	Tocopheryl Acetate
Surface Wash	91.48
Epidermis	7.13
Dermis	1.39
Dermis/Epidermis Ratio	0.20

Summary Of Results

- (a) The T, TP and T2P in the DSS and TPC formulations penetrate into the skin more effectively than TA.
- 5 (b) TPC is a better delivery system than DSS as shown by a higher TP penetration ratio into the dermis/epidermis.
- (c) The enhanced penetration of the tocopheryl phosphates from TPC is most likely the result of the TPC surface-active properties. The TPC is more effective in lowering the surface tension at the liquid/skin interface

10 compared to both DSS and TA. The latter is the most hydrophobic of the three test materials and forms a poor dispersion in the water/alcohol vehicle.

The word 'comprising' and forms of the word 'comprising' as used in this description and in the claims does not limit the invention claimed to exclude any variants or additions.

Modifications and improvements to the invention will be readily apparent to those skilled 15 in the art. Such modifications and improvements are intended to be within the scope of this invention.

WHAT IS CLAIMED IS:

1. A composition comprising the reaction product of:
 - (a) one or more phosphate derivatives of one or more hydroxylated actives; and
 - (b) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.
2. A composition according to claim 1 wherein the complexing agents are selected from the group consisting of silicone surfactants, alkyl amino/amido betaines, sultaines, phosphobetaines, phosphitaines, imidazolium and straight chain mono and dicarboxy ampholytes, quaternary ammonium salts, and cationic alkoxylated mono and di-fatty amines.
3. A composition according to claim 1 wherein the complexing agent is N-lauryl imino di-propionate.
4. A composition according to claim 1 wherein the complexing agents are selected from tertiary substituted amines according to the following formula:



wherein R¹ is selected from the group comprising R⁴ and R⁴CO wherein R⁴ is straight or branched chain mixed alkyl radicals from C6 to C22;

20 R² and R³ are either both R⁵ or one R⁵ and one H wherein R⁵ is chosen from the group comprising CH₂COOX, CH₂CHOHCH₂SO₃X, CH₂CHOHCH₂OPO₃X, CH₂CH₂COOX, CH₂COOX, CH₂CH₂CHOHCH₂SO₃X or CH₂CH₂CHOHCH₂OPO₃X and X is H, Na, K or alkanolamine; and

25 wherein when R¹ is R⁴CO then R² may be (CH₃) and R³ may be (CH₂CH₂)N(C₂H₄OH)-H₂CH₂OPO₃Na or R² and R³ together may be N(CH₂)₂N(C₂H₄OH)CH₂COOH.

5. A composition according to claim 1 wherein the cationic surfactants are selected from the group comprising:

- (a) RN⁺(CH₃)₃ Cl⁻;

- (b) $[\text{R}_2\text{N}^+\text{CH}_3]_2 \text{SO}_4^{2-}$;
- (c) $\text{RCON}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_2\text{N}^+(\text{CH}_3)_2\text{C}_2\text{H}_4\text{OH}]_2 \text{SO}_4^{2-}$;
- (d) $\text{RN}[(\text{CH}_2\text{CH}_2\text{O})_x \text{CH}_2\text{OH}][(\text{CH}_2\text{CH}_2\text{O})_y \text{CH}_2\text{OH}]$ wherein x and y are integers from 1 to 50; and

5 wherein R is C8 to C22 straight or branched chain alkyl groups or mixed alkyl groups.

- 6. A composition according to claim 1 wherein the complexing agent is an amino acid selected from arginine, lysine or histadine.
- 7. A composition according to claim 1 wherein one or more of the hydroxylated actives is an electron transfer agent.
- 10. A composition according to claim 7 wherein the electron transfer agent is tocopherol.
- 9. A composition according to claim 1 wherein there is more than one phosphate derivative of one hydroxylated active.
- 15. 10. A composition according to claim 1 wherein there is more than one phosphate derivatives of more than one hydroxylated actives.
- 11. A therapeutic formulation for use on humans, animals or plants comprising:
 - (a) an effective amount of the reaction product of:
 - (i) one or more phosphate derivatives of one or more hydroxylated actives; and
 - (ii) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids; and
 - 20. (b) an acceptable carrier.

12. A method for improving the bioavailability of hydroxylated actives comprising the step of reacting:
 - (a) one or more phosphate derivatives of one or more hydroxylated actives; with
 - 5 (b) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.
13. A method according to claim 12 further comprising the step of adding an acceptable carrier.
- 10 14. A method for administering to a subject a therapeutic formulation with an effective amount of one or more hydroxylated actives comprising administering to the subject a formulation comprising:
 - (a) an effective amount of the reaction product of:
 - (i) one or more phosphate derivatives of one or more hydroxylated actives; and
 - 15 (ii) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids; and
 - 20 (b) an acceptable carrier.
15. A composition comprising the reaction product of:
 - (c) one or more phosphate derivatives of tocopherol; and
 - (d) one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids having nitrogen functional groups and proteins rich in these amino acids.
- 25 16. A composition comprising the reaction product of:
 - (a) one or more phosphate derivatives of one or more hydroxylated actives; and

WO 02/40034

PCT/AU01/01476

38

- (b) one or more complexing agents selected from the group consisting of amphoteric surfactants and cationic surfactants.

17. An ingestible composition comprising the reaction product of:

- (a) one or more phosphate derivatives of one or more hydroxylated actives; and
- 5 (b) one or more complexing agents selected from the group consisting amino acids having nitrogen functional groups and proteins rich in these amino acids.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU 01/01476

A. CLASSIFICATION OF SUBJECT MATTER

Int Cl⁷: A61K 31/662, 31/355, 7/48, 7/02, 7/075, 7/16, C07F 9/141, A61P 17/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: As above

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

AU: IPC as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPAT, CAPLUS: Tocopheryl phosphate, tocopherol phosphate, surf(), complex, gel

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6046181 A (OONISHI et al) 4 April 2000 Abstract, claims, Example A-10, Example B-11, Example B-23 and Example B-24	1, 2, 7-16
X	US 5387579 A (MEYBECK et al) 7 February 1995 Abstract, Example 1, 3, 4, 10	1, 2, 7-16
	Derwent Abstract Accession No. 98-071819/07, class B02 D2 JP 09309813 A (NONOGAWA SHOJI KK), 2 December 1997	1
X	Abstract	1, 2, 7-16

 Further documents are listed in the continuation of Box C See patent family annex

* Special categories of cited documents:	
"A" Document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
13 December 2001Date of mailing of the international search report
- 3 JAN 2002Name and mailing address of the ISA/AU
AUSTRALIAN PATENT OFFICE
PO BOX 200
WODEN ACT 2606 AUSTRALIA
E-mail address: pct@ipaaustralia.gov.au
Facsimile No.: (02) 6283 3929Authorized officer
STEVEN CHEW
Telephone No.: (02) 6283 2248

INTERNAL SEARCH REPORT

International application No.

PCT/AU 01/01476

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	STN File CA, Abstract 135: 226884, & JP 2000-58632A (NOF CORP) 3 March 2000 Abstract	1-17
A	Derwent Abstract Accession No 84-098344/16, Class B03, JP 9044-375A (SENJU SEIYAKU KK), 12 March 1984 Abstract	1-17

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/AU 01/01476

Box 1 Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 1-14, 16-17
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
the claims are so broad in scope that a complete search is not possible (continue in Box 1)

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNAL SEARCH REPORT

International application No.

PCT/AU 01/01476

Box 1

Claims 1-14, 16-17 relate to a composition comprising the reaction product of one or more phosphate derivatives of one or more and one or more complexing agents selected from the group consisting of amphoteric surfactants, cationic surfactants, amino acids and some proteins. The claims cover a very broad range of compounds whereas the application provides support within the meaning of Article 6 PCT and /or disclosure within the meaning of Article 5 PCT for only a limited number of such compounds. IN the present case, a complete search over the whole of the claimed scope is not feasible. Consequently the search has been carried out for those parts of the claims which appear to be supported and disclosed such as the examples with due regard to the general idea underlying the application

INTERNATIONAL SEARCH REPORT
Information on patent family membersInternational application No.
PCT/AU 01/01476

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member			
US	6046181	CN	1173869	EP	798305	US	5965750
		WO	9714705				
US	5387579	CA	2075201	EP	513104	EP	652010
		FR	2657526	US	5656618	US	5952001
		WO	9111189				

END OF ANNEX